

June 26, 2021

National Stock Exchange of India Ltd Exchange Plaza, 5th Floor, Plot No: C/1 G - Block, Bandra - Kurla Complex Bandra (East), Mumbai - 400 051	BSE Limited Corporate Relationship Department 1st floor, New Trading Ring Rotunda Building, P J Towers Dalal Street, Fort Mumbai - 400 001
---	---

Sub: Disclosures under Regulation 7(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015

Dear Sir/Madam

In accordance with the provisions of Regulation 7(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015, we are enclosing a declaration submitted by M/s. Dhanuka Laboratories Limited, Promoter to the company under Regulation 7(2) (a).

Kindly take the above on records.

Thanking you,

Yours faithfully,

For **Orchid Pharma Limited**



Nikita K
Company Secretary

Encl.: a/a

FORM C
Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015
[Regulation 7 (2) read with Regulation 6 (2)]-continual disclosure

Name of the company : Orchid Pharma Limited

ISIN of the company : INE191A01027

Details of change in holding of Securities of Promoter, Member of the Promoter Group, Designated Person or Director of a listed company and immediate relatives of such persons and other such persons as mentioned in Regulation 6(2)

Name, PAN No., CIN/DIN & address with contact nos.	Category of Person (Promoter/Member of the Promoter group/designated person /Directors/immediate relative to/others etc.,)	Securities held prior to acquisition/disposal		Securities acquired/disposed				Securities held post acquisition/disposal		Date of allotment advice/ acquisition of shares/ disposal of shares, specify		Date of intimation to company	Mode of acquisition/disposal (On-market/Public/rights/preferential offer/off market/intra-se transfer/ESOPs etc.,)	Exchange on which the trade was executed
		Type of security (For eg.,- Shares,Warrants,Convertible Debentures,rights-entitlement-etc.,)	No. & % of shareholding	Type of security (For eg.,- Shares,Warrants,Convertible Debentures,rights entitlement etc.,)	No.	Value	Transaction type (Purchase/sale /Pledge/Revocation/Invocation/others Please specify)	Type of securities (For eg.,- Shares,Warrants,Convertible Debentures- Rights-entitlement-etc.,)	No. & % of shareholding	From	To			
1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
M/s Dhanuka Laboratories Limited	Promoter	Equity shares	4,00,00,072 equity shares & 98%	Equity shares	32,80,115 equity Shares	1,601,616,153.42	Offer for sale*	Equity shares	3,67,19,957 & 89.96%	24.06.2021	25.06.2021	26.06.2021	Offer for Sale through designated windows of NSE Ltd and BSE Ltd*	NSE limited and BSE Limited
CIN NO.: U24100DL1993PLC052285														
PAN NO: AAACD2877R														
Address : 82, Abhinash Mansion, First Floor,														
Joshi Road, Karol Bagh, New Delhi-110005														
Contact no: 9560929417														

Details of trading in derivatives on the securities of the company by Promoter, member of the promoter group, designated person or Director of a listed company and immediate relatives of such persons and other such persons as mentioned in Regulation 6(2)

Trading in derivatives (Specify type of contract , Futures or Options etc.,)					Exchange on which the trade was executed	
Type of contract	Contract specifications	Buy		sell		
		Notional value	Number of units (Contracts* lot size)	Notional value		Number of units (Contracts* lot size)
16	17	18	19	20	21	22
NOT APPLICABLE						

Note: In case of Options, notional value shall be calculated based on Premium plus strike price of options.

For Dhanuka Laboratories Limited

Manish Dhanuka

Manish Dhanuka
Managing Director
Date: 26.06.2021
Place: New Delhi



Note: (i) "Securities" shall have the meaning as defined under regulation 2(1)(i) of SEBI (Prohibition of Insider Trading) Regulations, 2015.

(ii) Value of transaction excludes taxes/brokerage/any other charges

*Offer for Sale by M/s. Dhanuka Laboratories Limited (Promoters) through the stock exchange mechanism on a separate designated window of BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE") was for achieving the Minimum Public Shareholding of 10% in the Company, as prescribed under Rule 19A of the Securities and Contract Regulation (Rules), 1957 and Regulation 38 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015